Holen Sie sich die Stockscreener-App
87.65
3.42%
2.90
Handel nachbörslich:
87.80
0.15
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders - TradingView
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion - TradingView
Dexcom stock trades near 52-week high as continuous glucose monitoring growth supports valuation - Ad-hoc-news.de
Dexcom Inc (DXCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dexcom Inc (DXCM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dexcom Inc (DXCM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dexcom Selected as First Manufacturer in FDA's Innovative Digital Health Outcomes Program - HCI Innovation Group
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dexcom Inc (DXCM) Balance Sheet - TradingKey
Dexcom stock trades steady as glucose-monitoring growth supports valuation - Ad-hoc-news.de
Dexcom Inc|Price:71.540|Chg%:+1.060 - TradingKey
Does DexCom’s (DXCM) Longer-Wear G7 Approval Hint At A Durable Edge In Connected Diabetes Care? - simplywall.st
Dexcom stock trades near recent highs as diabetes tech growth supports valuation - AD HOC NEWS
FDA selects Dexcom as first participant in TEMPO pilot for digital health devices - MedTech World
DexCom Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
DXCM|Dexcom Inc|Price:73.585|Chg%:+2.045 - TradingKey
Dexcom Gets First Slot In FDA-CMS Pilot That Rewards Real-World Data At Scale - insights.citeline.com
Dexcom Inc (DXCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
FDA names Dexcom as first participant in digital health pilot - MedTech Dive
DexCom (DXCM) Earnings Expected to Grow: Should You Buy? - Yahoo Finance Singapore
Dexcom Kicks Off FDA’s TEMPO Digital Health Device Pilot - Medical Product Outsourcing
Dexcom Inc (DXCM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dexcom (DXCM) Chosen as First Participant in FDA's TEMPO Pilot - GuruFocus
Dexcom stock trades near record levels as glucose monitoring demand supports growth - Ad-hoc-news.de
Dexcom (DXCM) Selected for FDA's TEMPO Pilot Program to Enhance Glucose Monitoring - GuruFocus
DexCom, Inc.'s Stock Price Drops to $71.43, Marking a 4.44% Decrease: Uncovering the Reasons Behind the Downfall - Smartkarma
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104.58 vs Price $71.43 - GuruFocus
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104. - GuruFocus
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Dexcom Investor Relations
DexCom Inc. stock underperforms Wednesday when compared to competitors - MSN
At US$74.75, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Dexcom Selected as First Participant in FDA's TEMPO Pilot Program - Intellectia AI
Dexcom Executive Chair Kevin R. Sayer Disposes of 26,756 Shares via Prearranged Rule 10b5-1 Plan - Kalkine Media
Dexcom Inc (DXCM) chair Kevin Sayer sells 26,756 shares under 10b5-1 plan - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
Dexcom stock trades near 52-week high as G7 CGM growth supports earnings momentum - AD HOC NEWS
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Dexcom stock trades steady as diabetes CGM growth supports earnings outlook - Ad-hoc-news.de
Dexcom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Dexcom stock holds steady as investors weigh Q1 2026 growth - ad-hoc-news.de
Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4 - TradingView
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Dexcom stock trades steady as diabetes technology growth supports valuation - ad-hoc-news.de
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. Stock Climbs 7.2%, Outperforms Market - webull.com
DXCM5813816 Bond Profile — Key Metrics - TradingView
Form 4 DexCom Inc For: 16 July By Investing.com - Investing.com Nigeria
Dexcom stock trades steady as CGM demand supports revenue growth - ad-hoc-news.de
Truist raises DexCom stock price target to $87 on growth outlook By Investing.com - Investing.com South Africa
Dexcom EVP chief legal compliance off sells $126,514 in stock By Investing.com - Investing.com Nigeria
DEXCOM INC : TRUIST SECURITIES RAISES TARGET PRICE TO $87 FROM $80 - Bitget
ETFs Investing in DexCom, Inc. Stocks - TradingView
DexCom Inc (DXCM) Stock Up 7.2% and Still Undervalued -- GF Scor - GuruFocus
Truist raises DexCom stock price target to $87 on growth outlook - Investing.com Nigeria
DexCom, Inc.’s stock price soars to $77.98, marking a remarkable 7.22% increase - Smartkarma
Dexcom EVP chief legal compliance off sells $126,514 in stock - Investing.com
DEXCOM INC (DXCM) EVP reports 1,700-share planned stock sale in Form 4 - Stock Titan
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why DexCom (DXCM) Stock Is Up Today - Quiver Quantitative
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):